BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27655283)

  • 21. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
    Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
    Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
    Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
    Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
    Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
    Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
    Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
    Yabushita S; Fukamachi K; Tanaka H; Fukuda T; Sumida K; Deguchi Y; Mikata K; Nishioka K; Kawamura S; Uwagawa S; Suzui M; Alexander DB; Tsuda H
    Carcinogenesis; 2013 Jun; 34(6):1251-9. PubMed ID: 23393225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
    Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study.
    Zhao R; Ren S; Li C; Guo K; Lu Z; Tian L; He J; Zhang K; Cao Y; Liu S; Li D; Wang Z
    Cancer Med; 2023 Feb; 12(4):5158-5171. PubMed ID: 36161527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.
    Martín-Blázquez A; Jiménez-Luna C; Díaz C; Martínez-Galán J; Prados J; Vicente F; Melguizo C; Genilloud O; Pérez Del Palacio J; Caba O
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic cancer screening using a multiplatform human serum metabolomics system.
    Sakai A; Suzuki M; Kobayashi T; Nishiumi S; Yamanaka K; Hirata Y; Nakagawa T; Azuma T; Yoshida M
    Biomark Med; 2016 Jun; 10(6):577-86. PubMed ID: 27171159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
    Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
    Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
    Luo X; Liu J; Wang H; Lu H
    Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma.
    Mahajan UM; Alnatsha A; Li Q; Oehrle B; Weiss FU; Sendler M; Distler M; Uhl W; Fahlbusch T; Goni E; Beyer G; Chromik A; Bahra M; Klein F; Pilarsky C; Grützmann R; Lerch MM; Lauber K; Christiansen N; Kamlage B; Regel I; Mayerle J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
    Parikh DA; Durbin-Johnson B; Urayama S
    J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.